| NCT ID | NCT07697248 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Life Raft Group |
| Condition | GIST |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,000 participants |
| Start Date | 2013-04 |
| Primary Completion | 2099-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,000 participants in total. It began in 2013-04 with a primary completion date of 2099-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Life Raft Group (LRG) Patient Registry is a structured database that collects comprehensive information about individuals diagnosed with GIST. The purpose of this registry is to facilitate research, improve understanding of the disease, track patient outcomes, and ultimately enhance patient care.
Eligibility Criteria
Inclusion Criteria: 1. Gastrointestinal Stromal Tumor diagnosis 2. Provide written and informed consent Exclusion Criteria: \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07697248 clinical trial?
This trial is open to participants of all sexes, studying GIST. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07697248 currently recruiting?
Yes, NCT07697248 is actively recruiting participants. Contact the research team at patientregistrydepartment@liferaftgroup.org for enrollment information.
Where is the NCT07697248 trial being conducted?
This trial is being conducted at Wayne, United States.
Who is sponsoring the NCT07697248 clinical trial?
NCT07697248 is sponsored by The Life Raft Group. The trial plans to enroll 5,000 participants.